The increasing global burden of type 2 diabetes (T2DM) is of considerable concern at the individual patient level as well as public health level. The goal of this learning activity is to provide doctors with a concise review of the current unmet needs in T2DM management, and how fixed-ratio combination (FRC) of insulin and glucagon like peptide-1 receptor agonist (GLP-1 RA) can potentially address these unmet needs. Upon completing this module, participants will have a better understanding of the following aspects:

• Patterns of insulin use in Malaysia

• Unmet needs in T2DM management

• Benefits of FRC therapy

• Switching from basal insulin to FRC therapy

CPD Reviewer:  

Dr Chan Siew Pheng

Honorary Professor

MBBS (Mal), FRCP (Edinburgh), AM (Mal)

Consultant Endocrinologist

Who should participate:

Doctors

NOTE :

Please read thoroughly & understand the module before attempting the assessment questions.

Terms & Conditions:

■ Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point.

■ MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points

The modules/articles are best viewed with:

Google Chrome, Firefox, Internet Explorer, Safari or any other W3C standards-compliant browser may be required to view the modules.

Supported by: